DentalMonitoring: July Product Announcements
21.7.2022 09:00:00 EEST | Business Wire | Press release
DentalMonitoring has launched a breakthrough service for dental professionals and industry partners: the DM Intelligent Platform is now the only digital workflow which can interface and integrate with all dental digital solutions available on the market today.
This industry-first accomplishment reinforces DentalMonitoring’s vision of making dentistry smarter, helping improve clinical outcomes and patient experience and enabling practice growth and efficiency.
Since 2014, DentalMonitoring has revolutionized the management of clinical care and practice workflows through its AI-powered solutions, championing the utilization of data to improve the quality of care. Our unique patented platform will greatly increase the freedom to operate and choice of partners for all dental professionals, and allow digital solution providers the ability to leverage DentalMonitoring’s unique AI technology.
The DM Intelligent Platform includes the following solutions:
- DataHub, a data analytics tool enabling continuous and immediate feedback and information to doctors, practices and partners related to clinical efficacy and operational efficiency
- Export of manufacture-ready STL files from monitoring scans without the need for an in-practice appointment*
- API/SDK Interfaces enabling integration of the DM Intelligent Platform with any digital partners, including patient management systems, CRM systems, digital treatment planning systems for aligners, braces and any other dental appliances, as well as devices such as connected electric toothbrushes.
“We’re excited that our unique technology trusted by thousands of doctors and more than 1.5 million patients worldwide will now be available to enhance product capabilities, workflows and solutions throughout the dental world,” says DentalMonitoring CEO Philippe Salah. “We believe that our only truly open digital platform in dentistry today positions us well to continue to positively impact the sustainability of dental care and improve the lives of millions of patients”. We invite all our doctors and partners to leverage our technology to its full potential and help us in our vision to make dentistry smarter.”
About DentalMonitoring - www.dental-monitoring.com
DentalMonitoring was started with a simple idea: oral care should be connected and continuous — even outside the practice. The company has created the world’s first virtual practice platform in dentistry, protected by over 200 patents, to address rapidly evolving patient expectations. Thanks to the largest database of dental images in the industry, DentalMonitoring has developed the most advanced and comprehensive doctor-driven AI solutions to help dental professionals provide superior care and a better patient experience. From patient lead engagement and conversion, providing treatment options through AI-generated reporting and advanced smile simulations, to remote monitoring of all types of treatments, DentalMonitoring’s unique platforms give dental professionals complete control over streamlined assessments and communication. DentalMonitoring has over 500 employees across 18 countries and 9 offices including Paris, Austin, London, Sydney and Hong Kong.
*Products availability, claims and regulatory status may differ across countries depending on local regulations. Contact your local representative for further information.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220720005916/en/
Contact information
Press Contact: Charlotte Garzino c.garzino@dental-monitoring.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Regnology Completes Acquisition of Moody’s Regulatory Reporting & Asset and Liability Management (ALM) Solutions5.5.2026 09:00:00 EEST | Press release
Regnology, a global provider at the intersection of regulatory, risk, finance and supervisory technology, today announced the completion of its acquisition of Moody’s Regulatory Reporting & ALM Solutions business. The transaction expands Regnology’s solution portfolio with Moody’s comprehensive capabilities covering Basel III compliance, IFRS 9 impairment, large‑bank asset and liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting. The transaction closes at a pivotal inflection point. Financial institutions face intensifying regulatory scrutiny, growing data complexity, and rising expectations for governance and auditability, while advances in artificial intelligence are creating new opportunities to modernize control frameworks and operating models. Regnology is responding by accelerating its Straight-Through Reporting (STR) vision and leveraging the combined capabilities of the transaction to deliver more resilient, transparen
AB InBev Reports First Quarter 2026 Results5.5.2026 08:02:00 EEST | Press release
Anheuser-Busch InBev (Brussel:ABI) (BMV:ANB) (JSE:ANH) (NYSE:BUD): This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260504526109/en/ Regulated information1 “Cheers to beer - the strength of the category and the consistent execution of our consumer-centric strategy drove continued momentum across our footprint. We are investing behind our megabrands and innovations to lead and grow the category. With strong execution by our teams and major moments of celebration ahead, we are well positioned for 2026.” – Michel Doukeris, CEO, AB InBev Revenue +5.8% Revenue increased by 5.8% with revenue per hl growth of 4.5%. Reported revenue increased by 12.0% to 15 267 million USD, positively impacted by currency translation. 8.2% increase in combined revenues of megabrands, led by Corona, which grew by 16% outside of its home market. 27% increase in revenue of no-alcohol beer. 37% increase in revenue of Beyond Beer. 55% increase in Gross Mer
Kerecis Drives the Fish-Skin Conversation at Leading European Wound Conference - EWMA-DEWU 20264.5.2026 21:25:00 EEST | Press release
Kerecis, the company pioneering the use of sustainably sourced intact fish skin in cellular therapy and tissue regeneration, will play a prominent scientific and educational role at the EWMA‑DEWU 2026 Conference, taking place May 6–8 at the Messe & Congress Centrum Bremen in Bremen, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260504487743/en/ MariCell® Solid This year, The European Wound Management Association's (EWMA) meeting is held in conjunction with the Deutscher Wundkongress (DEWU); combining two major wound-care congresses into a single forum for scientific exchange, education, and clinical discussion. At this year’s conference, Kerecis will highlight growing clinical experience with intact fish‑skin grafts across a broad range of wound indications, supported by two Kerecis‑led scientific symposia, multiple oral and poster presentations, and direct engagement with clinicians at Booth D30, located adjacent
Printing the Future of Medicine: CTIBIOTECH™ Announces $27 Million Investment to Launch U.S. Operations at the SelectUSA Investment Summit4.5.2026 21:00:00 EEST | Press release
CTIBIOTECH™, a pioneering Contract Research, Development, and Manufacturing Organization (CRDMO) and global leader in 3D bioprinting of human tissues, today officially announces the launch of its North American subsidiary, CTIBIOTECH USA™. The official launch took place today at the prestigious SelectUSA Investment Summit in Washington, D.C. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260504107996/en/ From Biopsy to Breakthrough, CTIBIOTECH USA™'s Vision for Precision Medicine Operating from its new United States base in the thriving life sciences “Cellicon Valley” hub of Philadelphia, Pennsylvania, in association with BioLabs for Advanced Therapeutics, CTIBIOTECH USA™ will provide the company's proprietary human cell and tissue bioassays and New Approach Methods (NAMs) directly to North American pharmaceutical, biomedical, and dermatocosmetics markets. By producing and supplying these cutting-edge human bioassays domesti
Kubota Vision Inc. Signs Supply and Licensing Agreement with Laboratoires KÔL for Stargardt Disease Treatment Candidate Under Compassionate Use4.5.2026 18:16:00 EEST | Press release
Kubota Vision Inc. (“Kubota Vision”), a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Minato-ku, Tokyo, Japan) announced signing of a Supply and Licensing Agreement with Laboratoires KÔL (Clermont-Ferrand, France) for the provision of a Stargardt disease (STGD1) treatment candidate under compassionate use authorization. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260414590785/en/ The purpose of this Agreement is for Kubota Vision and KÔL to collaborate on providing “Emixustat” for treatment of Stargardt Disease (STGD1) through compassionate use authorization in France. Kubota Vision will exclusively manufacture and supply Emixustat final products to KÔL and KÔL will have exclusive rights to distribute Emixustat in France under compassionate use access. Ryo Kubota, Chairman, President, and CEO of Kubota Pharmaceutical Holdings, stated, “We are extremely pleased to enter into this Agreement with Labor
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom